Metabolic Diseases  >>  PF-06291874  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
PF-06291874 / Pfizer
NCT02175121: Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 As Oral Monotherapy To Treat Adults With Type 2 Diabetes Mellitus

Completed
2
172
US
Placebo, PF-06291874
Pfizer
Diabetes Mellitus, Type II
03/15
03/15

Download Options